KCNH2 and Familial short QT syndrome: In recent years, studies using the human induced pluripotent stem cells (hiPSCs) derived to cardiomyocytes (CMs) have allowed to identify appropriate drugs for SQTS, especially type 1 (due to pathogenic variants in the KCNH2 gene) (El-Battrawy et al. 2018; Zhao et al. 2019).